PLAY PODCASTS
The IMID Forum

The IMID Forum

431 episodes — Page 5 of 9

Author Interview: Roy Fleischmann

Professor Roy Fleischmann, Clinical Professor of Medicine at the University of Texas Southwestern Medical Centre. In this addition Professor Fleischmann discusses his recent paper 'Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.'

Jan 18, 202321 min

Author Interview: Claudia Salinas

Dr Claudia Salinas, Director Pharmacoepidemiology at Eli Lilly and Company, Indianapolis, USA. In this addition Dr Salinas discusses her recent paper 'Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease registries and Claims Databases.'

Jan 13, 202336 min

Discussing Rheumatology: December 2022

Join Prof Iain McInnes as he reviews two interesting papers. The first highlights one of the three systematic literature reviews carried out to inform the 2022 EULAR RA management recommendations task force with the available evidence published since 2019. The second paper in today’s podcast looks at the recommendations themselves, by Smolen, et al, and I’ll highlight what’s remained the same and what’s changed from the 2019 recommendations. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dec 23, 202210 min

Discussing AxSpA: Episode 4

Join Professor Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications details the 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis. The second of today’s papers explores the efficacy and safety of bDMARDs in axSpA managment. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dec 14, 202226 min

Discussing Rheumatology: November 2022

Join Prof Iain McInnes as he reviews two interesting papers. The first paper aimed to compare the risk of MACEs and VTEs for patients initiating a JAKinib (tofacitinib and baricitinib) and those initiating adalimumab (TNFi) among a large and comprehensive real-world population of patients with RA. Our second paper aimed to evaluate the efficacy and safety of FIL200 and FIL100 compared with placebo and ADA, all with background MTX, in patients with MTX-IR RA in subgroups of those with all four PPFs versus those with fewer than four PPFs. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Nov 24, 202210 min

Discussing PsA: Episode 4

Join Professor Iain McInnes and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in October 2022. Our first paper seeks to examine the efficacy and safety of ixekizumab in patients with PsA and PsO. Our second paper today will highlight the comparative efficacy of multiple treatments in PsA utilising new data within an NMA framework. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Nov 9, 202224 min

Discussing Rheumatology: October 2022

Discussing Rheumatology: October 2022 by The Immune-Mediated Inflammatory Disease Forum

Oct 28, 202213 min

Discussing AxSpA: Episode 3

Join Professors Iain McInnes and Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the feild of axSpA theraputics, providing their own insights and experience into two very interesting publications. The first of our publications reports the efficacy and safety results for patients treated with ixekizumab for up to 116 weeks. The second of today’s papers evaluated the effectiveness and safety profile of COMBIO, or Combination of Targeted Therapies, in clinical settings. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Oct 12, 202222 min

Discussing Rheumatology: September 2022

Join Prof Iain McInnes as he reviews two interesting papers. The first covers the impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis. The second discusses infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Sep 28, 202212 min

Author Interview: Eduardo Mysler

Dr Eduardo Mysler, from the School of Medicine, University of Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Mysler discusses his recent paper 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'

Sep 28, 202230 min

Discussing PsA: Episode 3

Join Professors Iain McInnes and Phillip Mease as well as Doctors Frank Behrens and Laura Coates as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in August 2022. Our first paper aims to highlight the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients by looking at a single tender point out of the six-point LEI. The second of today’s papers evaluates the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial. Finally, our third paper reports the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Sep 13, 202237 min

Author Interview: Ameen Jubber

Dr Ameen Jubber, specialist registrar in rheumatology at the University Hospitals of Leicester NHS Trust, in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Jubber discusses his recent editorial paper reviewing the evidence for VTE risk in JAKinibs, and whether this risk also extends to the second-generation JAKinibs.

Aug 22, 202221 min

CSF Monthly Podcast August22

Join Prof Iain McInnes as he reviews two interesting papers. The first covers new data from China on the first-in-human trial of KL130008. The second reports on the exposure-response analyses of filgotinib for dose confirmation. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Aug 22, 20228 min

Author Interview: Kim Lauper

Dr Kim Lauper, from the Division of Rheumatology, Department of Internal Medicine and Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneve, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Lauper discusses her latest paper; Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration.

Aug 10, 202221 min

Discussing AxSpA: Episode 2

Join Prof. Baraliakos and Dr Mehta as they discuss the latest top research in axSpA. In this edition, our Steering Committee members look at three key papers published in July 2022. Our first paper investigated upadacitinib efficacy and safety in axSpA. The second of today’s looks at factors associated with drug-free remission in early onset axSpA patients. Finally, our third paper focuses on the association of bDMARD treatments with hospital acquired infections. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Aug 8, 202222 min

Discussing Rheumatology: July 2022

Join Prof Iain McInnes as he reviews two interesting papers from May and June. The first -by Faquetti , et al.- provides some insightful information into the pharmacological effects of tofacitinib and baricitinib. Our second paper then goes on to evaluate the real-life effectiveness and safety outcomes of four current second-line therapies of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Jul 28, 20229 min

Discussing PsA: Episode 2

Join Professors McInnes and Nash as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in May 2022. Our first paper highlights investigations of imaging characteristics and clinically assess heel enthesitis in SpA. The second of today’s paper evaluates the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab. Finally, our third paper reports the efficacy and safety of deucravacitinib in patients with active PsA. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Jul 27, 202226 min

Author Interview: Diego Kyburz

Author Interview: Diego Kyburz by The Immune-Mediated Inflammatory Disease Forum

Jul 25, 202217 min

Discussing Rheumatology: June 2022

Discussing Rheumatology: June 2022 by The Immune-Mediated Inflammatory Disease Forum

Jul 18, 20228 min

Discussing axSpA: Episode 1

Discussing axSpA: Episode 1 by The Immune-Mediated Inflammatory Disease Forum

Jun 24, 202218 min

Discussing PsA: Episode 1

Join Dr Laura Coates, Prof Enrique Soriano, Prof Chris Ritchlin, and Ass Prof Frank Behrens for our first podcast dedicated to the latest publications in PsA! In this edition, our Steering Committee members look at three key papers published in May 2022. The first, from Egeberg et al, looks at drug survival using a large, nationwide cohort study from the DANBIO and DERMBIO registries. The second looks at pooled data from SELECT-PsA-1 and -2 to investigate the safety profile of upadacitinib versus adalimumab in patients with active PsA and IR to biologic/non-biologic DMARDs. And finally, our speakers discuss new data from Merola et al on the effect of secukinumab CV risk factors and inflammatory biomarkers. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Jun 7, 202229 min

DAY 4: EULAR 2022 Daily Highlights

Douglas Veale takes you through our top picks from the selection of abstracts presented at the final day of EULAR 2022 (Saturday 4 June). Today's podcast covers RA, PsA, and axSpA.

Jun 4, 202218 min

DAY 3: EULAR 2022 Daily Highlights

Douglas Veale takes you through our top picks from the selection of abstracts at EULAR 2022 today (Friday 3 June). Today's podcast covers RA, PsA, and axSpA.

Jun 3, 202228 min

DAY 2: EULAR 2022 Daily Highlights

Laura Coates takes you through our top picks from the selection of abstracts at EULAR 2022 today (Thursday 2 June). Today's podcast covers RA, PsA, and axSpA.

Jun 2, 20226 min

DAY 1, PsA: EULAR 2022 Daily Highlights

Laura Coates takes you through our top picks from the selection of psoriatic arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!

Jun 1, 202212 min

DAY 1, RA: EULAR 2022 Daily Highlights

Laura Coates takes you through our top picks from the selection of rheumatoid arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!

Jun 1, 202213 min

DAY 1, axSpA: EULAR 2022 Daily Highlights

Laura Coates takes you through our top picks from the selection of axial spondyloarthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!

Jun 1, 202210 min

EULAR 2022 Preview Podcast

EULAR 2022 Preview Podcast by The Immune-Mediated Inflammatory Disease Forum

May 27, 20229 min

Discussing Rheumatology: May 2022

Join Prof Iain McInnes as he reviews two interesting papers published in May 2022! The first – from Bartlett et al – looks at the impact of tofacitinib on fatigue, sleep and HRQoL in patients with RA. While the second assesses the impact of JAKi or abatacept on RA-interstitial lung disease. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

May 25, 20227 min

Author Interview: Professor Peter Taylor

Professor Peter Taylor, from the University of Oxford in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Peter Taylor discusses pain control in early RA treated with baricitinib monotherapy.

Apr 28, 202223 min

Discussing Rheumatology: Pain, pneumonia and perspectives

Prof Iain McInnes reviews three papers this month!. The first – from Taylor et al – looks at pain control in early RA treated with baricitinib, the second investigates the immunogenicity of pneumococcal vaccination in patients with RA receiving upadacitinib and MTX, and the third paper is a perspective on regulatory changes in the wake of the ORAL SURVEILLANCE results. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Apr 28, 202213 min

Author Interview: Professor Rüdiger Müller

Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Rüdiger Müller discusses his paper on the impact of switching tofacitinib dose in patients with RA.

Apr 12, 202214 min

Discussing Rheumatology: March 2022

Discussing Rheumatology: March 2022 by The Immune-Mediated Inflammatory Disease Forum

Apr 12, 202211 min

Author Interview: Professor Roy Fleischmann

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the long-term safety and efficacy of upadacitinib or adalimumab in patients with RA.

Mar 16, 202219 min

Discussing Rheumatology: Tofacitinib safety and dose-switching in RA

Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Feb 24, 20227 min

ACR1540 Ana Rita Cruz - Machado

ACR1540 Ana Rita Cruz - Machado by The Immune-Mediated Inflammatory Disease Forum

Feb 11, 20225 min

ACR1087 Omar Alsaed

ACR1087 Omar Alsaed by The Immune-Mediated Inflammatory Disease Forum

Feb 11, 20225 min

ORAL Surveillance Author Interview – Roy Fleischmann

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the ORAL Surveillance study into CV and cancer risks with tofacitinib in patients with RA.

Feb 9, 202237 min

Author Author Interview: Professor Kevin Winthrop

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the clinical management of HZ in patients with RA or PsA receiving tofacitinib.

Feb 3, 202217 min

Discussing Rheumatology: HZ and ILD with tofacitinib in RA

Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease (ILD), an extra-articular manifestation of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Jan 27, 20226 min

Discussing Rheumatology: Safety of filgotinib, and tofacitinib in pJIA

Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dec 23, 20218 min

Author Interview: Professor Kevin Winthrop (December 2021)

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the safety of filgotinib in patients with RA.

Dec 23, 202122 min

Author Interview: Professor Kevin Winthrop (November 2021)

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the incidence and risk of herpes zoster in patients with RA receiving upadacitinib.

Dec 22, 202120 min

Insights at ACR 2021: Basic Science / Beyond RA

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Dec 14, 202140 min

Insights at ACR 2021: PROs and JAK Treatment

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Dec 13, 202148 min

Insights at ACR 2021: Clinical Outcomes in RA

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Dec 12, 202147 min

Insights at ACR 2021: JAKs in Spondyloarthritis

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Dec 11, 202130 min

Insights at ACR 2021: COVID-19 Vaccination and Rituximab

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Dec 10, 202131 min

Insights at ACR 2021: Impact of COVID-19 on Practice

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Dec 9, 202139 min

Insights at ACR 2021: COVID Vaccinations

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Dec 7, 202140 min